ConductScience.org, home

Comparison · NCT00623623-4592f433

Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Total Stroke (All Types)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Total Stroke (All Types). Trial comparisons, record NCT00623623-4592f433. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00623623-4592f433

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01580.00960.0259wilson
Risk in group 20.005270.002250.0123wilson
Risk difference, group 1 minus group 20.01050.001170.0211newcombe hybrid score
Risk ratio, group 1 over group 231.098.21log
Odds ratio, group 1 over group 23.031.18.37log
Number needed to treat, for one more participant with the outcome on Tenecteplase (Group A) than on Primary PCI (Group B)9547.4856from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Tenecteplase (Group A)
Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)
15949OG000
Group 2Primary PCI (Group B)
Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.~Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.
5948OG001

Outcome

Type
SECONDARY
Title
Number of Patients With Total Stroke (All Types)
Description
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported
Time frame
30 days
Population
FAS

Source ClinicalTrials.gov

Trial

Title
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
NCT number
NCT00623623
Phases
PHASE3
Conditions
Myocardial Infarction
Interventions
primary PCI, enoxaparin, catheterisation, tenecteplase, clopidogrel
Lead sponsor
Boehringer Ingelheim
Results first posted
2019-08-01

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00623623-4592f433